Life Sciences Archive » January, 2018

Life Sciences - January, 2018

373 articles

• Teikoku Swears Off Pay-For-Delay In Lidoderm Deal With AGs
• Renal Clinics Will Pay $4M To Settle Investors' Fraud Claims
• J&J Baby Powder Contained Asbestos, Expert Tells Jury
• Axing Restasis Patents Would Stifle Innovation, PhRMA Warns
• Danish Watchdog Says CD Pharma Abused Its Dominance
• Patent Owners Should Think Hard Before Giving Up At PTAB
• Shkreli Sentencing Delayed While Parties Mull Loss, Forfeiture
• Investors Blast NuVasive's Sanctions Bid Over Depositions
• FTC Looks To Beat Suit Challenging Its Authority
• GAO Blocks Big Biz Protest On FDA Small Biz Software Deal
• Pharmacist Gets 8 Years For Making Meningitis-Linked Drugs
• AbbVie Seeks New Trial After $140M AndroGel Verdict
• Daiichi Wins Enforcement Of $550M Ranbaxy Award In India
• Life Sciences Group Of The Year: King & Spalding
• Centers Of Influence Are Key To Small Law Firm Rainmaking
• NH Asks Justices To Deny Endo's Challenge Of Outside Atty
• Ensuring Section 121 Safe Harbor Applies To Patent
• Medtronic Investors Win Cert. In Revived Stock-Drop Suit
• Life Tech Rips Promega Bid To Rethink US Damages In IP Row
• Fed. Circ. Says PTAB Erred In Axing Part Of Surgical Patent
• Aegerion Sentenced To Pay Patients In Twist On $36M Plea
• Mass. AG's Medicaid Fraud Dept. Got $45M Back In 2017
• FDA Warning Wire: Drugmaker Misled Customers About Tests
• Consumers Urge 9th Circ. To Revive Costco Labeling Suit
• Meet The Judge Who's Steering The Epic Opioid MDL
• No Asbestos In J&J Talc, NJ Jury Told In Mesothelioma Case
• Ex-Teva Exec Didn't Violate CFAA In Sharing Info With Lover
• Struggling Teva Pharmaceutical Plans To Raise $5B In Debt
• Life Sciences Group Of The Year: Williams & Connolly
• Accutane Suits Filed Too Late, NJ Panel Affirms
• Pfizer Expects $15B Tax Bill For Overseas Assets
• Akorn, Fera, Perrigo Settle Trade Secrets, Antitrust Suit
• Cymbalta Users Try To Revive Case After High Court Setback
• Irish Medical Device Co. Pockets €40M In Funding Round
• TC Heartland And Hatch-Waxman: Square Peg In Round Hole
• The Future Of France Is Innovation
• Trial Over J&J Talc, Mesothelioma Link Kicks Off In NJ
• Investors Seek Early OK For $290M Valeant, Pershing Deals
• New DOJ Memo Will Make Waves In Fraud Cases
• Forest Beats Final Cases In Celexa, Lexapro MDL
• Patent Deal Clears Actavis' Zohydro Generic For 2029
• Pharmacist Should Pay Meningitis Victims $82M, Gov't Says
• 6 More Cos. Launch IPOs Totaling $1.4B As Pipeline Grows
• Kite Pharma Investors Seek Appraisal After $11B Gilead Buy
• From Law Firm To Newsroom: An Interview With Bob Woodruff
• Ex-Dentist Cops To $16.6M Medical Device Fraud
• Health-Focused VC Firm Rebrands, Launches $100M Fund
• EU Extends Deadline For Bayer-Monsanto Review
• Novartis Blasts Attempt To Revive Pay-For-Delay Suit
• Life Sciences Group Of The Year: Paul Hastings
• Sanofi Beats Novo To Buy Ablynx For $4.8B
• Judging A Book: Kendall Reviews 'On The Jury Trial'
• Gene-Edited Crops Ripe For Renewed Regulatory Focus
• What's At Play In First J&J Talc Asbestos Trial
• High Court Denies Helsinn's Bid To Stay On-Sale Bar Ruling
• Equistone Sells Off Life Sciences Co. In £163M Deal
• Kimberly-Clark, Others To Pay $3.9M In Bay Pollution Spat
• Ixchel On Last Legs With Antitrust Claims Against Biogen
• Mylan Pradaxa Generic Delayed In Boehringer Patent Deal
• New Orleans Doc Gets 10 Years For Running Opioid 'Pill Mill'
• Don't Miss It: Hot Deals & Firms We're Following This Week
• AbbVie Drug Did Not Cause Man's Blood Clots, Jury Finds
• How Cos. Can Take Advantage Of DOJ False Claims Act Memo
• FDA Must Explain Amgen Exclusivity Denial, Judge Rules
• Health Hires: Frost Brown, EBG, McDermott, Dykema Cox
• Life Sciences Group Of The Year: Fish & Richardson
• Cannabis Co.'s Tribal-Land Op Suit Moved To State Court
• 7 Cos. To Price IPOs Exceeding $3.4B Led By Gaming REIT
• Takeda, Lilly Escape Already-Settled Diabetes Drug Claims
• Taxation With Representation: Weil, Proskauer, Debevoise
• CBRE Director Sees 'Frantic Rush' As Biotech Space Evolves
• FCA Memo No Proof Of New DOJ Direction On Dismissals
• FDA Lawfully Denied Exclusivity For Namenda Generic: Judge
• Medicis Falls Short In Bid To Escape Pay-For-Delay Suit
• LivaNova Wants Consolidation Of Bacteria Exposure Suits
• Allergan, Restasis Buyers Can't Agree On MDL Venue
• Shareholders Sue Cancer-Drug Maker Over $1.7B Roche Deal
• Lyondell Trustee Can't Recover $300M Payment To PE Mogul
• Greenberg Traurig Adds Deals Pro From Mitchell Silberberg
• PE-Backed Gates Industrial Leads 3 IPOs Raising $878M
• Attys React To DOJ's New Memo On FCA Dismissals
• Real Estate Rumors: Fortis, Blackstone, Soon-Shiong
• Patients Seek Calif. MDL In Suits Over Diabetes Drugs
• Asacol Antitrust Trial Delayed To Let Allergan Appeal Class
• Do I Need New Trial Counsel? 9 Questions To Ask
• Forest Beats Bid For More Docs In Celexa, Lexapro MDL
• Illumina Wins $27M Prenatal Test IP Verdict Against Ariosa
• Cooley Leads Pot PE Fund To Close $100M Series C Round
• Groups Warn Against NAFTA Changes That Raise Drug Prices
• A Look At Chemical Supplemental Examination Requests
• Feds Push To Expand FCA Billing Suit Against Fresenius
• Express Scripts Escapes Shareholder Class Action
• FDA, Endo Freeze High-Stakes Drug Compounding Case
• Deals Rumor Mill: Weinstein Co., Luye, Microsemi
• Medical Device Co. To Pay $7.6M In Electrode FCA Suit
• Mass.' New US Atty Keeps Heat On Pharma Donations
• Grocers Slam Teva, Mylan Over Drug Price-Fixing 'Conspiracy'
• ABA, INTA Urge Full Fed. Circ. To Kill USPTO Fee Rule
• Fed. Circ. Upholds PTAB Ruling In Suture Patent Case
• Shire Rips Allergan's 'Stranglehold' On Dry-Eye Drug Market
• Rite Aid Customers Sue Over Excessive Generic Rx Copays
• FDA, FTC Target Opioid Addiction Treatment Claims
• 10 Antitrust Developments And Trends To Watch In 2018
• Allergan Vies For Insurance Coverage Lists In Asacol Trial
• Senate Confirms Eli Lilly, Wiley Rein Vet To Lead HHS
• Bodybuilding Co. Says Steroid-Alternative Suit Lacks Detail
• Aurora Cannabis' $890M CanniMed Deal Ends Takeover Fight
• Rite Aid To Pay $4M Over Improper Meth Ingredient Sales
• Illumina, Ariosa Seek Tens Of Millions As IP Trial Ends
• Aetna To Pay $1.15M To New Yorkers Hit By HIV Info Breach
• 1st Circ. 'Reluctantly' Nixes Sanctions In $70M Fine Appeal
• Texas Fracker Leads 3 Cos. Launching IPOs Totaling $440M
• DLA Piper Adds 2 Partners To Chicago Office
• EU Court Backs €183M Fine In Italian Drug Antitrust Case
• Revere Sues Pharma Cos. Over Opioids, Boston Might Follow
• Fed. Circ. Backs PTAB's Invalidation Of J&J Remicade Patent
• Medline Says TC Heartland Doesn't Apply To Bard Transfer Bid
• Pharma Can't Be Liable For Generics, GSK Tells 7th Circ.
• Israeli Info Crucial To $163M Perrigo Tax Row, IRS Says
• Omnicare Settles DOJ's Citizenship Discrimination Probe
• FDA Warning Wire: Web Sales Of Banned Obesity Drug
• NYC Sues Drugmakers, Distributors Over Opioid Epidemic
• Health Care, Life Sciences M&A To Stay Strong In 2018
• Lessons From President Trump's Failed Judicial Nominations
• J&J Hit With $13.6B Charge Under New Tax Law
• Video-Averse Plaintiffs' Atty Has Been Abusive, Puma Says
• Zydus Gets FCA Claims Trimmed In Generics Pricing Row
• Patient Info Not A Kickback, MedImmune Says In Fraud Suit
• High Court Considers Upending Patent Damages
• IP Owners Group Says USPTO Fees Rule Is 'Crippling'
• Fed. Circ. Bats Down Helsinn Bid To Stay On-Sale Bar Ruling
• Fenwick IP Partner Tapped As Calif. Fed. Magistrate Judge
• Express Scripts Beats Pharmacy's Antitrust Suit
• FDA Faces $50M Suit After Discrediting Drug Research Co.
• Cherokee Nation Takes Opioid Claims To Okla. State Court
• Attorneys Squabble Over Cut Of $785M Pfizer FCA Deal
• UPDATED: Medtech Startup Drops Suit Against Would-Be CEO
• Justices Asked To Weigh Patentability Of Natural Processes
• Whole Foods Overloads Supplements With B12, Suit Says
• German Surgical Toolmaker Cut From NJ Cancer Death Suit
• 11th Circ. Upholds Amgen, Pfizer Win In Infection Suit
• Lab Owner Never Agreed To Be Face Of Sex Drug, Suit Says
• How To Control Data As Technology Complicates E-Discovery
• Clashing Marijuana Laws Create Insurer Anxiety
• Celgene Continues Active January With $9B Juno Acquisition
• Sanofi Buys Hemophilia Drugmaker In $11.6B Deal
• Immigration Standoff Keeps Government Shuttered
• Lab's Peptide IP Suit May Run Aground On Safe Harbor
• '#Killinnazis' Uproar Shows Attys Must Tread Lightly Online
• Del. Becomes Latest To Sue Pharmas Over Opioid Crisis
• 7th Circ. Won't Revive Claims Of 1,000 Pfizer Suits In MDL
• Fed. Circ. OKs Gilstrap Erasing Jury's Invalidity Verdict
• 9 IPOs Projected To Exceed $3B In Year's Busiest Week
• Abbott, Plaintiffs Seek Stay Of Depakote Suits, Pending Talks
• Cornell, Life Tech Must Arbitrate IP Settlement Fight
• Merck Loses Bid To Revive Antibiotic Patent In Fed. Circ.
• Helsinn Wants On-Sale Bar Ruling Held For High Court Appeal
• 2017 Health Care Enforcement Review: Final Thoughts
• Fed. Circ. Presens Ruling Provides Insights On Prior Art
• GSK Says Families Too Late To Amend Zofran MDL
• Janssen Sues Teva To Stop Generic Of Schizophrenia Drug
• Prosecutor Flustered By Surprise Motions At Insys Hearing
• Generics Co. Resists Allergan's Bid To Leave Restasis IPRs
• 4 Key Takeaways From FDA's 2017 Enforcement Stats
• House OKs Spending Bill To Head Off Gov't Shutdown
• Fake Medical Pot Certifications Get Fla. Atty Disbarred
• 9th Circ. Urged To Revive Prostate Supplement Labeling Row
• 3 Antitrust Cases Drug Companies Should Watch This Year
• 2017 Health Care Enforcement Review: Materiality Under FCA
• Argentum Wins Invalidation of J&J Unit's Cancer Drug Patent
• Deals Rumor Mill: CBS, J&J, Weinstein Co.
• Merck, Glenmark Stifled Cholesterol Drug Market, Suit Says
• AndroGel Can Cause Blood Clots Many Ways, Doc Tells Jury
• Investor Gets 1 Year For Insider Trading On Gilead Buy
• Calif. County Wants Tribe's Suit Over Hemp Seizure Nixed
• IRS Delays Penalty For Excise Tax On Medical Devices
• Chamber Backs GSK In 3rd Circ. Flonase Rehearing Bid
• Puma Biotech Investors Say Depo Camera Is Meant To Harass
• Pa. Court Urged To Resurrect Actiq Off-Label Marketing Suit
• House May Vote On Spending Bill Delaying ACA Taxes
• J&J Unit Can't Nix FCA Suit Over Hip Implants Yet
• Ex-Sen. Dodd, Eli Lilly Litigation Head Join Arnold & Porter
• Hep C Meds Patent Row Can't Stay In Minn., Fed. Circ. Says
• Ex-Aveo Exec Says SEC Exaggerated Role In Investor Fraud
• Philly Becomes Latest To Sue Drugmakers For Opioid Crisis
• Drugmaker Urges Full Fed. Circ. To Kill USPTO Fee Rule
• Removal In 2017: How Defendants Got To Federal Court
• 2017 Health Care Enforcement Review: FCA Case Law
• A Chat With Davis Wright CSO Mark Usellis
• Fed. Circ. Clarifies But Won't Redo AIA On-Sale Bar Ruling
• FDA Warning Wire: Allergan Gets New Ammo Against Rival
• NJ Lab Sues Horizon Over Coverage For Women On Medicaid
• Smith Stratton Joins Dilworth Paxson In Like-Minded Merger
• Allergan Deal Clears 2031 Launch Of Sun's Linzess Generic
• Purdue's 'Duplicative' Suit Over OxyContin Generic Gets Ax
• America's Shifting Views On Marijuana Post-Cole Memo
• 5 Cos. Launch IPOs Surpassing $1B As January Gains Steam
• Insurers Accused Of Blocking Allergy Testing Competition
• NJ Opioid Laws Tackle Rx Fraud, Nix Antidote Liability
• High Court Won't Consider Atty Fees In Medtronic Case
• 2017 Health Care Enforcement Review: Trends In FCA Cases
• A Definiteness Reminder For Pharmaceutical Patent Drafters
• A Momentous Year For CFIUS: Part 2
• The Firms That Dominated In 2017
• Law360 Names Practice Groups Of The Year
• 1st Circ. Sends 3 More Meningitis Pharmacists To Trial
• Valeant Says Insurers Must Defend Allergan, Stock-Drop Suits
• Valeant Sees Most Claims Against It Stick In Stock-Drop Suits
• Tribe Says Immunity Unscathed By Joining Allergan IP Suit
• Pfizer's Hospira Billed Gov't For Faulty Pumps, Suit Says
• 3 Firms To Steer IPOs Totaling $2.5B As Deal-Making Resumes
• PTAB To Review Tyvaso Patents Despite Time-Bar Protest
• Drug, Device Makers Cheer As FDA Punts Off-Label Policy
• Investors Want Abbott To Explain Delay In Alere Deal
• Shkreli Hits Back At Feds' $7.3M Forfeiture Bid
• Atty's Malpractice Jurisdiction Fight Dies At Texas High Court
• Ex-Insys Manager's Opioid Kickback Trial Pushed To Sept.
• Balancing Vertical Integration In Calif.'s Cannabis Industry
• Justices To Hear Chinese Vitamin C Price-Fixing Case
• A Survey Of In-House Attorney Views On Trade Secrets
• A Momentous Year For CFIUS: Part 1
• Applying BMS To Federal Class Actions: Due Process Matters
• NJ's Evolving Health Care Arena: Trends To Watch In 2018
• DOJ Ups Estimate Of FCA Whistleblower Recoveries
• Teva Investors Fight Bid To Nix Price-Fixing Suit
• Restasis Is FDA-Approved, Allergan Reminds Compounder
• 1st Circ. Chides Biolitec For Umpteenth Appeal Of $70M Fine
• Dr. Scholl's Shoe Inserts Aren't Custom Fit, 2nd Circ. Told
• Opioid Addiction Treatment Co. Nabs $110M For New Product
• Fla. Compounding Pharmacy, Execs Escape Rep's FCA Claims
• US Blasts Raytheon Escape Bid In Mass. Cleanup Liability
• Amgen, Genentech Await Del. Ruling In Biosimilar IP Row
• DQ King & Spalding In Vaccine Patent Row, Ex-Client Says
• Novartis' Zortress Patent Survives PTAB Challenge
• 6 E-Discovery Predictions For 2018
• Murky FDA Device Guidance Kills Sanofi Antitrust Suit
• Endo Hit With Subpoena For Opioid-Related Docs
• The Latest Fed. Circ. Approach To 'Inference Of Intent'
• What I Learned In My 1st Year: Read The Whole Thing
• Pharma Charity's Suit Tests OIG's Kickback Oversight
• Allergan's Restasis Patents Are Valid, Fed. Circ. Told
• Yale Doc Fights To Keep Fees After Beating Defamation Suit
• Former Sedgwick Partner Lands At Porzio Bromberg
• Saul Ewing Adds Ex-Sedgwick Partners In Miami, New York
• No Quick Road Ahead For Pa. Risperdal Punitives, Attys Say
• BakerHostetler Grows Corporate Practice With Stradling Hire
• No Tribal Jurisdiction In Cherokee Opioid Suit, Judge Says
• Supplement Co., FTC Settle Cancer Treatment Product Suit
• Settlement Aspirations Enter The Opioid MDL
• Bayer, Merck Want Suit Questioning Coppertone SPF Tossed
• Simmons Nabs Ex-CMS London Atty For New Patent Group
• Law360's Pay-For-Delay Case Cheat Sheet For 2018
• 3-D Printed Implants Pose Challenge For Product Regulators
• 6 Roles To Embrace In An Evolving Legal Industry
• Ariosa, Illumina Spar Over Patent Timing In DNA Test Trial
• Baupost Hit With $4M Short-Swing Suit Over Innoviva Stock
• Allergan Wants Out Of Restasis Patent Challenges
• Perrigo Fights Deposition Of Dexcel Workers In $163M Bout
• Deals Rumor Mill: Siemens, Akamai, GSK
• Apotex Gets PTAB To Trim OSI's Cancer Drug Patent
• Mass. US Atty Won't Rule Out Pot Prosecutions Post-Reversal
• Pa. Judge Junks $28M Xarelto Verdict Against J&J, Bayer
• HHS Nominee Eyes New Tacks On Drug Prices, Provider Pay
• FTC Lawyers Slam LabMD's Retaliation Suit In DC Circ.
• Aggrenox End-Payors Reach $54M Deal In Pay-For-Delay Suit
• Will Life Sciences Companies Face More Scrutiny In 2018?
• Cannabis Co. Hits Back At Tribal Corp.'s Dismissal Bid
• SD Tribes Add To Flood Of Opioid Marketing Suits
• Hagens Berman, Others Want $31M In Pfizer Celebrex Deal
• Judge Urges Speedy Pace For Opioid MDL Amid Crisis
• This Year, Let's Invest In Lawyer Resiliency
• Amici Views On Big Pharma 'Renting' Sovereign Immunity
• High Court Declines To Review 7 IP Cases
• Genomics IP Trial Between Illumina And Ariosa Kicks Off
• Docs Weren't Warned About AndroGel's Risks, Jury Told
• Endo Gets OK To Join FTC's Impax Pay-For-Delay Case
• Allergan Fights To Keep Live Testimony In Asacol Trial
• Doc's Attys Duel Over Fee Split In $785M Pfizer FCA Deal
• Supreme Court Declines To Rehash Stryker Noncompete Win
• GSK Wants 3rd Circ. To Rehear La. Flonase Decision
• Seattle Genetics Mounts 3rd Bid To Defeat Stock Fraud Suit
• CSL Must Face Shire's Willful Infringement Claim
• 5 Legal Technology Predictions For 2018
• Deals Rumor Mill: Dermapharm, Aramco, Life Healthcare
• OFAC Enforcement Trends In 2017: Exporters On Notice
• J&J May Face Punitive Damages In Pa. Risperdal Cases
• Restasis Antitrust Suits Paused For MDL Panel Review
• Womble Bond Adds Ex-Taylor English Patent Pro In Atlanta
• Belgian Biotech Ablynx Pushes Aside $3.1B Novo Nordisk Bid
• Indirect Purchaser Cases In 2017: Key District Court Rulings
• 3 Enforcement Priorities For State AGs In 2018
• Why Physician Choice Matters In Medical Product Cases
• AbbVie Faces Third Jury In Testosterone MDL
• PTAB Scolds Tribe Over Unauthorized Impartiality Motion
• Covidien Nears OK For Stay Of California IP Suit
• VC-Backed Israeli Biopharma Co. Launches $55M IPO
• OIG Allows Free Drugs After Axing Charity's Kickback Shield
• Ex-ArthroCare Exec Gets 4 Years In $750M False Sales Plot
• Thermo Fisher, Phadia To Exit Allergy Test Antitrust Suit
• Lawyers Head To JPMorgan Conference Eager To Spark Deals
• NC Cherokee Tribe Latest To File Opioid Marketing Suit
• Judge Sticks By Approval Of $350M Shire FCA Deal Split
• Valeant Hit With Investment Funds' Fraud Scheme Suit In NY
• NJ Biotech Co. Closes $76M Financing Round
• Health Hires: DEA, Womble Bond, LeClairRyan Bulk Up In DC
• Allergan Target Faces Bid To Halt Vote On $30M Merger
• DLA Piper Guides Takeda In €520M Biopharma Acquisition
• Jury Misconduct Claimed In Ex-Katten Atty Trial
• Atty In $28M Xarelto Trial Could Be Nixed Over Judge Photo
• NY Surgical Instruments Co. Hit With Junk-Fax Claims
• Court Divide Could Spur More Hatch-Waxman Venue Fights
• A Look At Recent Efforts To Contain Health Care Costs
• Top 4 Health Care Cybersecurity Threats For 2018
• Gilead Takes Key FCA Battle To Supreme Court
• The Broader Implications Of Sessions' Marijuana Move
• Pharma Distribution Group Says Antitrust Suit Is Nonsense
• FDA Warning On Stem Cell Co. Keeps Up Heat On Industry
• More Relators Push FCA Cases To The End In 2017
• Transposagen Can't Use TC Heartland To Nix Antibody IP Suit
• Lead Attys Named For Massive Opioid MDL
• TerraVia Holdings Moves Ahead With Ch. 11 Liquidation
• Allergan Announces Reduction Of 1,000 Jobs
• Sessions' Reversal Likely To Kill Any Pot Buzz For Banks
• Fed. Circ. Revives Infringement Row Over Pill Coating
• Sessions Reverses Obama-Era Marijuana Enforcement Policy
• Celgene Hits Supplier With Cancer Drug Trademark Suit
• Janssen Gets $5.6M Verdict Tossed In Calif. Appeals Court
• 3rd Circ. Affirms CSL's Win In Employee Retaliation Suit
• 9th Circ. Won't Rethink Costco's Win In Apotex Origin Case
• Roche Maintains Suppliers Broke Test-Strips Contract First
• Pa. Marijuana Investors Cut Out License Preparer, Suit Says
• Litigation Finance Trends To Watch In 2018
• 5 Health Care Policy Issues To Follow In 2018
• Why Sales Rep Witness Tampering Accusations Matter
• Shire, Ultragenyx Settle Row Over 'Trade Secret' Doctor List
• Omnicare Deemed Joint Employer In Drivers' Wage Suit
• Mass. Gynecologist Loses Bid For Grand Jury Instructions
• Aviragen Stockholder Sues For Meeting Before $60M Merger
• Generics Buyers Fight To Keep 2 Drugs In Antitrust MDL
• 3rd Circ. Backs Nix Of Pharmacies' Claim In Lipitor MDL
• Mohawk Tribe Demands Info On 'Impartiality' Of PTAB Judges
• DNA Data Co. Gets $58M From Google, Microsoft, VC Firms
• Pot Exec Says Atty's Arbitration Pact Doesn't Apply To Him
• LeClairRyan Sued For Malpractice By Ex-Blood Test Exec
• Drug Buyers Can't Get Forest Labs Docs Related To Probe
• Judge Sets Busy Trial Slate For Philly Testosterone Cases
• FDA Unveils Guidance To Smooth Generic-Drug Path
• The Enneagram And The Practice Of Law
• Shook Hardy Brings On Ex-Sedgwick Chair
• Alissa Starzak On Net Neutrality, US Army, Leap To Startup
• Amgen Says It Didn't Mislead On Biosimilar Marketing Date
• Chinese Medical Marketplace Closes $60M Funding Round
• FDA Issues Highest-Level Recall For J&J Heart Device
• Funds Say Valeant Price-Gouging Probe Cost Them $80B
• Pershing, Valeant Agree To $290M Deal Ending Allergan Suits
• Ex-Katten Atty Conviction A Cautionary BigLaw Tale
• Sloan Kettering Gets Trimmed Fees In IP Fight
• Biotech Cos. Lead 7 Post-Christmas IPO Filings
• Lupin, Sandoz Settle With Retailers In Solodyn Suit
• FDA Warning Wire: Diet Drug Deceit, Fresenius Failings
• Auxilium Settles 1st Philly Testosterone Case
• Massachusetts Marijuana Regulatory Scheme Takes Shape
• Judging A Book: Tymkovich Reviews 'Gorsuch'
• Pear Therapeutics Closes Temasek-Led $50M Funding Round
• Bristol-Myers, Consumers Look To Centralize NJ Abilify Suits
• The Hottest Patent Law Issues Of 2017
• Key New Jersey Cases To Watch In 2018
• Life Sciences Regulation To Watch In 2018
• Illinois Cases To Watch In 2018
• Life Sciences Cases To Watch In 2018
• California Cases To Watch In 2018
• Patent Cases To Watch In 2018
• 5 Things To Watch For In FCPA Enforcement This Year